Sanofi and Regeneron present more positive data for Dupixent product

Reuters

PARIS (Reuters) – Healthcare companies Sanofi and partner Regeneron presented on Tuesday more positive data for their Dupixent product.

The companies said new data showed that Dupixent showed a significant histological remission of eosinophilic esophagitis in children 1 to 11 years old. Eosinophilic esophagitis is a chronic inflammatory disease that damages the esophagus and prevents it from working properly.

(Reporting by Sudip Kar-Gupta; Editing by Christian Schmollinger)

Related News:   Brazil Lula's approval, disapproval statistically even, poll shows

tagreuters.com2022binary_LYNXMPEI9A06Y-BASEIMAGE

tagreuters.com2022binary_LYNXMPEI9A071-BASEIMAGE

You appear to be using an ad blocker

Shore News Network is a free website that does not use paywalls or charge for access to original, breaking news content. In order to provide this free service, we rely on advertisements. Please support our journalism by disabling your ad blocker for this website.